Skip to main content
SpringerLink
Log in

Pitavastatin: a guide to its use in hypercholesterolaemia and mixed dyslipidaemia

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Pitavastatin (Livazo®; Livalo®), an HMG-CoA reductase inhibitor (statin), is an effective and well tolerated option to reduce elevated total cholesterol and low-density lipoprotein cholesterol levels in adults with primary hypercholesterolaemia and mixed dyslipidaemia, including those considered to be at high risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

Similar content being viewed by others

References

  1. Reiner Z, Catapano AL, Backer GD, et al. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32: 1769–818

    Article  PubMed  Google Scholar 

  2. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 Nov 13; 376 (9753): 1670–81

    Article  PubMed  CAS  Google Scholar 

  3. Sukhija R, Prayaga S, Marashdeh M, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009 Mar; 57 (3): 495–9

    PubMed  CAS  Google Scholar 

  4. Baker WL, Talati R, White CM, et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Prac 2010 Jan; 87 (1): 98–107

    Article  CAS  Google Scholar 

  5. Livazo® 1, 2 and 4 mg tablets: summary of product characteristics. Wokingham, UK: Kowa Pharmaceutical Europe Co. Ltd, 2011 Aug

  6. Livalo® (pitavastatin) tablets 1 mg, 2 mg, and 4 mg: prescribing information. Montgomery (AL): Kowa Pharmaceuticals America, Inc., 2012 Feb

  7. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 1997 Aug; 47 (8): 904–9

    PubMed  CAS  Google Scholar 

  8. Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000; 7 (3): 138–44

    PubMed  CAS  Google Scholar 

  9. Duggan ST. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia. Drugs 2012; 72 (4): 565–84

    Article  PubMed  CAS  Google Scholar 

  10. Ose L, Budinski D, Hounslow N, et al. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia [published erratum appears in Curr Med Res Opin 2010 May; 26 (5): 1046]. Curr Med Res Opin 2009 Nov; 25 (11): 2755–64

    PubMed  CAS  Google Scholar 

  11. Budinski D, Arneson V, Hounslow N, et al. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009; 4 (3): 291–302

    Article  CAS  Google Scholar 

  12. Eriksson M, Budinski D, Hounslow N, et al. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Adv Ther 2011 Sep; 28 (9): 811–23

    Article  PubMed  CAS  Google Scholar 

  13. Stender S, Budinski D, Gosho M, et al. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol. Epub 2012 Jun 7

  14. Gumprecht J, Gosho M, Budinski D, et al. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab 2011 Nov; 13 (11): 1047–55

    Article  PubMed  CAS  Google Scholar 

  15. Data on file, Kowa Pharmaceutical Europe Co. Ltd, 2011.

  16. Ose L, Budinski D, Hounslow N, et al. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia [published erratum appears in Atherosclerosis 2010 Oct; 212 (2): 704]. Atherosclerosis 2010 May; 210 (1): 202–8

    Article  PubMed  CAS  Google Scholar 

  17. Eriksson M, Budinski D, Hounslow N, et al. Long-term efficacy of pitavastatin versus simvastatin. Adv Ther 2011 Aug 25; 28 (9): 799–810

    Article  PubMed  CAS  Google Scholar 

  18. Stender S, Budinski D, Hounslow N. Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol. Epub 2012 Jan 23

  19. Catapano AL. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Curr Vasc Pharmacol 2012 Mar; 10 (2): 257–67

    Article  PubMed  CAS  Google Scholar 

  20. Teramoto T. Pitavastatin: clinical effects from the LIVES study. Atheroscler Suppl 2011 Nov; 12 (3): 285–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements and Disclosures

This article was adapted from Drugs 2012; 72 (4): 565-84,[9] and reviewed by L. Mascitelli, Medical Service, Comando Brigata Alpina “Julia”, Udine, Italy; L. Ose, Lipid Clinic, Oslo University Hospital, Oslo, Norway.

The preparation of these articles was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson & Sean T. Duggan

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sean T. Duggan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A., Duggan, S.T. Pitavastatin: a guide to its use in hypercholesterolaemia and mixed dyslipidaemia. Drugs Ther Perspect 28, 5–9 (2012). https://doi.org/10.1007/BF03262119

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262119

Keywords

Search

Navigation